A Belfast biotech firm says it’s continuing its work in tackling coronavirus and remains “confident” that its technology can “help to accelerate finding a solution to this global health crisis”.
Paul Kerr, chief executive of Fusion Antibodies, said that “on these currently extremely challenging times, we now have the resources to undertake the additional proof-of-concept work on the ‘mammalian antibody library discovery platform in respect of Covid-19, as well as for our existing oncology targets, whilst continuing to support our clients in their vital role”.
“We remain confident that our products and services can help to accelerate finding a solution to this global health crisis,” he said.
Fusion Antibodies recently announced it’s now part of the Northern Ireland Coronavirus Antibody Development Alliance, set up to help in the global fight against the coronavirus pandemic.
The business specialises in pre-clinical antibody discovery, engineering and supply.
In its latest trading update, the listed company said some of its targets include “accelerating proof of concept by investigating unmet need both for Covid-19 solutions as well as oncology targets”.
It said it is “delivering ahead of targets and the mammalian antibody library is literally 'game-changing' as successful outcomes can enable FAB to target much higher value markets”.
“Initially from fees for service and subsequently by means of licensing fees and royalties. While markets clearly remain volatile, these new opportunities help demonstrate the continuing high relevance and versatility of antibodies in developing healthcare solutions.”